Prevalence of Ischemia on Myocardial Perfusion Scintigraphy of Pre-and Postmenopausal Women

Daniel Augusto Message dos Santos, Wendy Yasdin Sierraalta Navarro, Leonardo Machado Alexandre, Priscila Feitosa Cestari, Paola Emanuela Poggio Smânio
Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brazil

Abstract

Background: In postmenopausal women, the presence of risk factors for coronary artery disease (CAD) increases. However, the difference in prevalence of ischemia between pre- and postmenopausal women with multiple risk factors for CAD has not been well established.

Objectives: To compare the prevalence of ischemia on Tc\textsuperscript{99m}-sestamibi myocardial perfusion scintigraphy (MPS) in pre- and postmenopausal women, and to evaluate whether menopause can be considered an independent risk predictor of ischemia in women with multiple risk factors for CAD.

Methods: This study retrospectively assessed 500 MPS of pre- and postmenopausal women with multiple risk factors for CAD. Statistical analysis was performed by using Fisher exact test and univariate and multivariate analysis, a p value ≤ 0.05 being considered significant.

Results: Postmenopausal women represented 55.9% of the sample; 83.3% were hypertensive; 28.9%, diabetic; 32.1%, smokers; 25%, obese; 61.2% had high cholesterol levels; and 34.3% had known CAD. Postmenopausal women were more often hypertensive, diabetic and dyslipidemic, and had lower functional capacity on exercise testing (p = < 0.005). The presence of ischemia on MPS did not significantly differ between the pre- and postmenopausal groups (p = 0.395). The only variable associated with ischemia on MPS was known CAD (p = 0.004).

Conclusion: The results suggest that, in women with multiple risk factors for CAD, menopause was not an independent predictor of ischemia on MPS. Those data support the idea that the investigation of ischemia via MPS in women with multiple risk factors for CAD should begin prior to menopause. (Arq Bras Cardiol. 2013; 101(6):487-494)

Keywords: Myocardial Ischemia/radionuclide imaging; Women; Premenopause; Posmenopause; Risk factors.

Introduction

It was only recently that the major studies on coronary artery disease (CAD) began to include women\textsuperscript{1-3}.

Women are usually more obese and smoke more than men; 25% of women have sedentary lifestyles, 52% of those over the age of 45 years have arterial hypertension and 40% of those over the age of 55 years have hypercholesterolemia\textsuperscript{1-2}. Diabetic women are at an extremely high cardiovascular risk, comparable to that of women who already had myocardial infarction, with more adverse outcomes\textsuperscript{4,5}.

The clinical manifestations of CAD appear approximately 10 to 15 years later in women, a fact possibly related to estrogen protection. With the increase in life expectancy, the postmenopausal period began to represent one third of a woman’s life, drawing more attention to that specific population\textsuperscript{1-2,6,7}.

Some of the traditional diagnostic tests for CAD investigation do not function so properly in the female sex, and evidence has suggested that they have a greater prognostic rather than diagnostic value for women\textsuperscript{8,9}.

Exercise testing provides important information, but its mean sensitivity and specificity are lower than in the male sex, around 61% and 69%, respectively\textsuperscript{10}. In addition, unspecific baseline electrocardiographic alterations of the ST segment, due to estrogenic hormone action, might generate tests whose results “falsely” suggest ischemia\textsuperscript{10}.

Myocardial perfusion scintigraphy (MPS) has become a highly important tool for diagnostic investigation in the female sex, particularly in women with unspecific alterations on baseline electrocardiogram and with low functional capacity or difficulty to achieve the proper heart rate, which is very common in the group of diabetic women and those with peripheral vascular disease\textsuperscript{11,12}. In addition, the reduction in breast attenuation artifacts and the acquisition of images guided by electrocardiography (gated-SPECT) increase the accuracy of the test, helping to differentiate real defects and artifacts\textsuperscript{13}.

Previous studies\textsuperscript{7,14} have reported that estrogenic protection is associated with a reduction in cardiovascular risk; however, there is scarce literature about the role of non-invasive diagnostic methods, especially Tc\textsuperscript{99m}-sestamibi MPS in pre/postmenopausal women, mainly in those with multiple risk factors for CAD.
Objectives
The present study aimed at comparing the presence of ischemia on Tc\textsuperscript{99m}-sestamibi MPS in pre/postmenopausal women at high risk for CAD, and at assessing whether menopause is an independent predictive factor of ischemia in that group of patients.

Methods
This is an observational, retrospective study carried out at the nuclear medicine sector of the Instituto Dante Pazzanese de Cardiologia, based on the review of medical records, analyzing consecutive 500 MPS of women performed in 2011 and 2012. This study was approved by the committee of ethics and research (02020312.7.0000.5462). All patients provided written informed consent before undergoing MPS.

Exercise and pharmacological (dipyridamole and dobutamine) stress test and acquisition and processing of nuclear medicine images were performed by using standard techniques, according to the guidelines of the Brazilian Society of Cardiology/Department of Ergometry, Exercise, Nuclear Cardiology and Cardiovascular Rehabilitation\textsuperscript{15,16}. Myocardial perfusion scintigraphy was performed by use of the gated-SPECT technique, one-day protocol, the baseline phase being followed by the stress phase. A GE Ventri dedicated cardiac gamma camera was used for image acquisition. To assess myocardial perfusion, the myocardium was divided into 17 segments. Normal perfusion was considered the absence of reduced uptake of the radiotracer in both phases (baseline and stress); perfusion suggestive of ischemia and fibrosis was considered the presence of reversible and fixed reduced uptake of the radiotracer after the stress phase as compared to the baseline phase, at least in 3 of the 17 myocardial segments analyzed\textsuperscript{15}.

The qualitative visual analysis of the presence or absence of perfusion alterations was performed by two observers specialized in cardiology and nuclear medicine, and, in case of disagreement, a third observer also specialized in cardiology and nuclear medicine was consulted.

This study considered the presence of myocardial ischemia on scintigraphy. Of all patients assessed, 69 had perfusion alterations suggestive of myocardial fibrosis, 41 of whom were postmenopausal women and 28, premenopausal (p = 0.069).

The patients were classified as pre/postmenopausal according to data in medical records.

The classical cardiovascular risk factors assessed were arterial hypertension, diabetes mellitus, dyslipidemia, smoking and obesity, defined according to the Brazilian Society of Cardiology guidelines\textsuperscript{17}.

Patients with known CAD were those with previous diagnosis of myocardial infarction, unstable/stable angina and percutaneous or surgical myocardial revascularization. In addition, patients with the following characteristics were considered to be at equivalent high cardiovascular risk: stroke; carotid and peripheral artery disease; abdominal aorta aneurysm; and chronic renal failure\textsuperscript{17}.

Patients with non-ischemic heart diseases and those with no information regarding menopause in their medical records were excluded.

Statistical analysis was performed with Fisher exact test and univariate and multivariate analyses, and the significance level adopted was p ≤ 0.05.

Results
Table 1 shows the clinical and epidemiological characteristics of the patients assessed according to their menopausal status.

The physicians of the outpatient clinics where the patients were followed up requested the MPS according to clinical indications. Such indications were divided into symptomatic and asymptomatic patients (Tables 2 and 3). Table 4 shows the results of the MPS in asymptomatic patients.

Tables 5 to 7 show the number of exercise stress tests and dipyridamole and dobutamine stress tests performed according to the menopausal status of the patients, as well as patients’ clinical and electrocardiographic characteristics, and physical fitness and functional capacity.

The degree of physical fitness, known as functional capacity, measured in metabolic equivalents (MET) on the exercise test was significantly lower in postmenopausal women. Of all patients, 91 reached 10 MET or less, 56 were postmenopausal

### Table 1 - Clinical and epidemiological characteristics of the pre- and postmenopausal groups

|               | Total (%) | Premenopausal N = 221 | Postmenopausal N = 279 | p value |
|---------------|-----------|------------------------|------------------------|---------|
| Mean age ± SD |           | 500 (100)              | 45.4 ± 4.16            | 65.7 ± 6.67 | < 0.001 |
| Hypertension  |           | 414 (83.3)             | 164 (74)               | 250 (89) | < 0.001 |
| Diabetes      |           | 144 (28.9)             | 36 (16)                | 108 (38) | < 0.001 |
| Dyslipidemia  |           | 305 (61.2)             | 100 (45)               | 205 (74) | < 0.001 |
| Smoker/ex-smoker |         | 160 (32.1)            | 70 (32)                | 90 (32) | 0.92 |
| Obesity       |           | 125 (25)               | 49 (22)                | 76 (28) | 0.213 |
| CAD           |           | 171 (34.3)             | 69 (31)                | 102 (37) | 0.218 |

CAD: previous coronary artery disease.
Santos et al. Schemia on Pre- and Postmenopausal Women Scintigraphy

Arq Bras Cardiol. 2013; 101(6):487-494

The only variable predictive of ischemia on MPS was the presence of previous CAD (p < 0.05).

Of the 500 patients assessed with MPS, ischemia was identified in 102 (58.5%) postmenopausal patients and in 72 (41.5%) premenopausal patients, with no statistical significance (p = 0.395).

Figure 1: Findings suggesting ischemia on the dipyridamole MPS of a 46-year-old female patient with diabetes, hypertension, obesity, dyslipidemia, sedentary lifestyle, and known CAD (sten in the anterior descending artery for three years): ECG showing ST-segment depression during the infusion of dipyridamole; and myocardial perfusion showing transient reduction in radiotracer uptake in the anterior, anteroseptal and apical walls.

Discussion

Diagnosing CAD in the female sex is a great challenge. Because its symptoms are less typical in women, non-invasive tests have an unquestionable value for its effective investigation in women before submitting them to invasive, sometimes unnecessary, tests. In the Coronary Artery Surgery Study (CASS), half of the women submitted to coronary angiography showed no significant lesions.

| Table 2 - Indications for MPS in symptomatic patients |
|------------------------------------------------------|
| **Functional test** | **Total** | **Premenopausal** | **Postmenopausal** |
|----------------------|-----------|-------------------|-------------------|
| MPS                  | 396       | 179               | 231               |
| **Indications**      |           |                   |                   |
| Atypical chest pain  | 169       | 87                | 82                |
| Typical chest pain   | 103       | 47                | 52                |
| Functional class worsening | 92       | 33                | 59                |
| Palpitations         | 20        | 8                 | 12                |
| Vertigo              | 4         | 0                 | 4                 |
| Syncope              | 8         | 4                 | 4                 |

*MPS: myocardial perfusion scintigraphy.*

| Table 3 - Indications for MPS in asymptomatic patients |
|-------------------------------------------------------|
| **Functional test** | **Total** | **Premenopausal** | **Postmenopausal** |
|----------------------|-----------|-------------------|-------------------|
| MPS                  | 104       | 42                | 62                |
| **Indications**      |           |                   |                   |
| Preoperative assessment | 5       | 3                 | 2                 |
| After PTCA/stent or CABG | 33     | 9                 | 24                |
| To assess the etiology of dilated cardiomyopathy   | 10       | 4                 | 6                 |
| To assess the etiology of arrhythmia                | 15       | 6                 | 9                 |
| To assess the etiology of LBBB                      | 2        | 0                 | 2                 |
| Other altered functional test                        | 14       | 10                | 4                 |
| Cardiovascular risk stratification or other non-specified reasons | 25    | 10                | 15                |

*MPS: myocardial perfusion scintigraphy; PTCA: percutaneous transluminal coronary angioplasty; CABG: coronary artery bypass graft surgery; LBBB: left bundle-branch block.*

| Table 4 - Subanalysis of asymptomatic patients |
|------------------------------------------------|
| Asymptomatic patients = 104 altered MPS = 60 patients | Premenopausal patients = 23 Postmenopausal patients = 37 |
| normal MPS = 44 patients                               | Premenopausal patients = 19 Postmenopausal patients = 25 |

*MPS: myocardial perfusion scintigraphy.*

and 35, premenopausal (p < 0.005). The only variable predictive of ischemia on MPS was the presence of previous CAD (p < 0.05).

Of the 500 patients assessed with MPS, ischemia was identified in 102 (58.5%) postmenopausal patients and in 72 (41.5%) premenopausal patients, with no statistical significance (p = 0.395).
Table 5 - Clinical and electrocardiographic characteristics and functional capacity on exercise stress testing

|                                         | Total | Premenopausal | Postmenopausal |
|-----------------------------------------|-------|---------------|---------------|
| Total                                   | 200   | 112           | 88            |
| Total of normal tests                   | 93    | 55            | 38            |
| Normal tests reaching > 10 MET           | 61    | 39            | 22            |
| Total of altered tests                  | 107   | 57            | 50            |
| ECG alteration                          | 40    | 23            | 17            |
| Alteration due to chest pain            | 41    | 24            | 17            |
| ECG alteration + chest pain             | 24    | 9             | 15            |
| Complex ventricular arrhythmia during the test | 2    | 1             | 1             |
| Altered tests reaching < 10 MET         | 91    | 44            | 47            |
| Other symptoms during the test          | 37    | 22            | 15            |
| Unspecific chest pain                   | 24    | 14            | 10            |
| Dyspnea                                 | 13    | 8             | 5             |
| Headache                                | 0     | 0             | 0             |

ECG: electrocardiography.

Table 6 - Clinical and electrocardiographic characteristics on dipyridamole stress testing

|                                         | Total | Premenopausal | Postmenopausal |
|-----------------------------------------|-------|---------------|---------------|
| Total                                   | 279   | 105           | 174           |
| Total of normal tests                   | 130   | 46            | 84            |
| Total of altered tests                  | 149   | 59            | 90            |
| ECG alteration                          | 31    | 9             | 22            |
| Alteration due to chest pain            | 69    | 31            | 38            |
| ECG alteration + chest pain             | 48    | 19            | 29            |
| Complex ventricular arrhythmia during the test | 1    | 0             | 1             |
| Other symptoms during the test          | 50    | 15            | 35            |
| Unspecific chest pain                   | 23    | 7             | 16            |
| Dyspnea                                 | 5     | 2             | 3             |
| Headache                                | 22    | 6             | 16            |

ECG: electrocardiography.

Table 7 - Clinical and electrocardiographic characteristics on dobutamine stress testing

|                                         | Total | Premenopausal | Postmenopausal |
|-----------------------------------------|-------|---------------|---------------|
| Total                                   | 21    | 4             | 17            |
| Total of normal tests                   | 9     | 0             | 9             |
| Total of altered tests                  | 12    | 4             | 8             |
| ECG alteration                          | 5     | 2             | 3             |
| Alteration due to chest pain            | 6     | 2             | 4             |
| ECG alteration + chest pain             | 1     | 0             | 1             |
| Other symptoms during the test          | 5     | 0             | 5             |
| Unspecific chest pain                   | 2     | 0             | 2             |
| Dyspnea                                 | 0     | 0             | 0             |
| Headache                                | 3     | 0             | 3             |

ECG: electrocardiography.
Figure 1 - Ischemia on myocardial perfusion scintigraphy of a premenopausal woman.
As our institution is a tertiary cardiological hospital, women followed up there usually have multiple risk factors for CAD, and most of them already had a previous myocardial infarction and/or myocardial revascularization procedure (as reported in this study, 34% with previous known CAD). Thus, we decided to carry out a study reflecting the reality of women referred for MPS, and those with previous CAD were not excluded.

The objective of this study was to assess whether menopause was an independent predictor of ischemia in women at our institution, with and without known CAD.

It is worth emphasizing that, in our study, many women had previous electrocardiographic alterations on baseline ECG and low functional capacity, which motivated their referral for MPS, aimed at diagnostic investigation and cardiovascular risk stratification.

As already observed, the choice and interpretation of non-invasive procedures are not easy tasks. Exercise testing is known to have lower sensitivity and specificity in the female sex than in the male sex18. The sensitivity and specificity of the pharmacological or exercise stress tests can be improved by imaging methods that increase diagnostic accuracy10,11,18. With the refinement of the technique, a reduction in attenuation artifacts (breast, for example) was observed, leading to greater specificity19.

In the present study, MPS proved to be an important tool to investigate ischemia, which was observed in 35% of the women assessed. Such data are in accordance with those of the literature. Smanio et al11, studying the MPS of 104 asymptomatic diabetic women, have reported myocardial ischemia in 34 (32.7%).

Myocardial scintigraphy plays a role in CAD diagnosis and cardiovascular risk stratification in both sexes, considering that it provides information on myocardial perfusion, left ventricular function and, if necessary, myocardial viability. Its combination with exercise testing, particularly in the female sex, significantly increases diagnostic accuracy7-19.

Mieres et al19 have assessed 46 postmenopausal women with exercise test and MPS, and the sensitivity and specificity values found were, respectively, 67% and 69% for the exercise test, and 88% and 87.5%, for MPS (p < 0.0001).

The prognostic importance of scintigraphy in the female sex is well known9,21. There is a large body of evidence on the association of myocardial scintigraphy and stress testing, showing that it effectively stratifies the risk in women suspected of having CAD. Women with a normal myocardial perfusion study have an annual event rate much lower (0.6% per year) than those with abnormal myocardial perfusion study (5% per year)22.

The lower cardiovascular risk in the premenopausal phase is attributed to the protection provided by plasma estrogen levels23,24. Such levels promote arterial vasodilation by increasing the nitric oxide synthesis by endothelial cells, increase HDL-cholesterol particles and decrease LDL-cholesterol particles, and reduce the serum levels of fibrinogen, antithrombin and protein S24.

The decreased estrogen levels of the postmenopausal phase lead to microvascular endothelial dysfunction and consequent progression of the atherosclerotic plaque21,24. Differently from the endogenous estrogen effects, exogenous hormone therapy has shown to increase the cardiovascular disease risks23-26.

In 2002, the Women’s Health Initiative (WHI) study showed that the benefits of hormone replacement therapy (HRT) were restricted to a small group of women in the so-called “window of opportunity”, at the beginning of menopause (between 50 and 59 years), in the presence of no cardiovascular risk factors. Recent studies have confirmed that information27. However, a recent publication of the American Heart Association (AHA) contra-indicates the use of HRT as primary and secondary prevention of cardiovascular diseases28.

Leuzzi et al29, in an interesting editorial, have reported that, despite the higher prevalence of CAD after menopause, further studies are required to clarify whether menopause is a cardiovascular risk factor.

The association between menopause and presence of CAD might be observed in low-risk women, but for those with multiple risk factors, such as diabetes, hypertension, dyslipidemia, obesity, sedentary lifestyle, as seen in our study, menopause might not be a predictive factor of ischemia. These same findings have been observed by Sood et al34 when assessing 2,194 pre- and postmenopausal women at an intermediate risk for CAD according to Duke score on exercise testing and according to MPS. In that study, menopause has not proved to predict cardiovascular events, and MPS provided risk stratification beyond the Duke score. A study with a larger number of patients should be performed to confirm that statement.

Conclusion

The results obtained suggest that, in women with multiple risk factors for CAD, menopause was not an independent predictor of ischemia on Tc99m-sestamibi MPS. The only proven predictor in that group was the presence of known CAD. Those data support the idea that the investigation of ischemia via MPS in women with multiple risk factors for CAD should begin prior to menopause.

Author contributions

Conception and design of the research, Acquisition of data, Analysis and interpretation of the data, Statistical analysis, Writing of the manuscript, Critical revision of the manuscript for intellectual content: Santos DAM, Sierralta WY, Alexandre LM, Smanio PE, Cestari PF.
Potential Conflict of Interest
No potential conflict of interest relevant to this article was reported.

Sources of Funding
There were no external funding sources for this study.

References

1. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Conner E, et al. Cardiovascular disease in women - A statement for healthcare professionals from the American Heart Association. Circulation. 1997;96(7):2468-82.

2. Smith J, Winston M, Zinberg S, Oparil S, Pasternak R, Pearson TA, et al. Guide to preventive cardiology for women. Circulation. 1999;99(18):2480-1.

3. Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104(4):499-503.

4. Halfin SM, D’Agostino R Jr, Mykkänen L, Tracy R, Howard B, Reweros M, et al. Insulin sensitivity in subjects with type 2 diabetes. relationship to cardiovascular risk factors: the insulin resistance atherosclerosis study. Diabetes Care. 1999;22(4):562-8.

5. Brandão AP, Brandão AA, Nogueira AR, Suplicy M, Guimarães JI, Oliveira JP, Sociedade Brasileira de Cardiologia. I Diretriz brasileira de diagnostico e tratamento da síndrome metabólica. Arq Bras Cardiol.2005;84(suppl 1):1-28.

6. Fernandes CE, Pinho-Neto SL, Gebara OCE, Santos Filho RD, Pinto Neto AM, Pereira Filho AS, et al; Sociedade Brasileira de Cardiologia, Sociedade Brasileira de Clínica Médica. I Diretriz brasileira sobre prevenção de doenças cardiovasculares em mulheres climatéricas e a influência da terapia de reposição hormonal (TRH). Arq Bras Cardiol. 2008;91(1 suppl 1):1-23.

7. Mieres JH, Shaw LJ, Arari A, Budoff MJ, Flamm SD, Hundley G, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease. Consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. Circulation. 2005;111(5):682-96.

8. Smanio PE. Fisiologia do sistema cardiovascular: o gênero feminino importa? Rev Soc Cardiol Estado de São Paulo.2009;19(4):466-73.

9. Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol. 2004;11(2):171-85.

10. Hlatky MA, Pryor DB, Harrell FE Jr, Califf RM, Mark DB, Rosati RA. Factors affecting sensitivity and specificity of exercise electrocardiography: multivariable analysis. Am J Med.1984;77(1):64-71.

11. Smanio PE, Carvalho AC, Tebezeni AS, Thom A, Rodrigues F, Meneghelo R, et al. Coronary artery disease in asymptomatic type-2 diabetic women: a comparative study between exercise test, cardiopulmonary exercise test, and dipyridamole myocardial perfusion scintigraphy in the identification of ischemia. Arq Bras Cardiol.2007;89(3):263-90,290-7.

12. Smanio PE. Cardiovascular disease in diabetic women without cardiac symptoms. Arq Bras Endocrinol Metabol. 2007;51(2):305-11.

13. Smanio PE, Watson DJ, Segalla DJ, Vinson EL, Smith WH, Heller GA. Value of gating of technetium-99m sestamibi single-photon emission computed tomographic imaging. J Am Coll Cardiol. 1997;30(7):1687-92.

14. Sood N, Kazzi FA, Lundbye JB, Katten D, Heller GV. Risk stratification of CAD with SPECT-MPI in women with known strogen status. J Nucl Cardiol.2012;19(2):330-7.

15. Chalewa WA, Meneghetti JC, Ximenes AAB, Almeida CA, Vitola Jv, Mastrocolla LE, et al; Sociedade Brasileira de Cardiologia. I Diretriz sobre cardiologia nuclear. Arq Bras Cardiol. 2002;78(suppl 3):1-42.

16. Meneghelo RS, Araújo CGS, Stein R, Mastrocolla LE, Albuquerque PF, Serra SM, et al; Sociedade Brasileira de Cardiologia. III Diretrizes sobre teste ergométrico. Arq Bras Cardiol. 2010;95(5 suppl 1):1-26.

17. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation. 1983;68(5):939-50.

18. Kwok Y, Kim C, Grady D, Segal M, Redberg R. Meta-analysis of exercise testing to detect coronary artery disease in women. Am J Cardiol. 1999;83(5):660-6.

19. Taillefer R, DePuyer G, Udelson JE, Beller GA, Latour Y, Reeves F. Comparative diagnostic accuracy of TI-201 and Tc-99m sestamibi SPECT imaging (perfusion and ECG-gated SPECT) in detecting coronary artery disease in women. J Am Coll Cardiol. 1997;29(1):69-77.

20. Berrizbeitia R, Makarius AN, Cacciabuono JM, Donaldson D, Green SJ, Heller GV, et al. Value of electrocardiographically gated single-photon emission computed tomographic myocardial perfusion scintigraphy in a cohort of symptomatic postmenopausal women. Am J Cardiol. 2007;99(8):1096-9.

21. Chakravorty L, Herman DS, Kiat H. Effective risk stratification using exercise myocardial perfusion SPECT in women: Gender-related differences in prognostic nuclear testing. J Am Coll Cardiol. 1996;28(1):34-44.

22. Gulati M, Shaw LJ, Bairey Merz CN. Myocardial ischemia in women: Lessons from the NHLBI WISE Study. Clin Cardiol. 2012;35(3):141-8.

23. Morise AP, Assessment of estrogen status as a marker of prognosis in women with suspected coronary artery disease presenting for stress testing. Am J Cardiol. 2006;97(3):367-71.

24. Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol. 2002;89(12A):12A-17A.

25. Pepine CJ, Balaban RS, Bonow RO, Diamond GA, Johnson BD, Johnson PA, et al. Women’s ischemic syndrome evaluation current status and future research directions. Report of the National Heart, Lung and Blood Institute Workshop: October 2-4, 2002:Section 1: Diagnosis of stable ischemia and ischemic heart disease. Circulation. 2004;109(6):e44-6.

26. Pineiro AM, Sturdee DW, Birkha MH. HRT in the early menopause: scientific evidence and common perceptions. Climacteric. 2008;11(4):2672.

27. Rossow JE, Anderson GL, Prentice RL, Lacroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321-33.

28. Mosca L, Benjamin EJ, Berra K, Beazion JH, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women 2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243-62.

29. Luessi C, Marzullo R, Modena MG. La menopausa e un fattore di rischio per la cardiopatia ischemica? G Ital Cardiol. 2012;13(6):401-6.
